Recruiting

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

United States

Retina Partners Midwest, P.C. /ID# 262172, Carmel, Indiana

Retina Research Institute of Texas /ID# 262141, Abilene, Texas

Retina Foundation of the Southwest /ID# 262479, Dallas, Texas

Retina Consultants - The Woodlands /ID# 262138, The Woodlands, Texas